Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.4. Antileprosy medicines | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. |
| PAHO Strategic Fund Medicine List | 2.2. Antileprosy med. |
Others observations: Medicines used in the treatment of leprosy should never be used except in combination. |
| Bolivia | LINAME 2011 - 2013 | No observations |
| Peru | 6.2.3 Anti-Leprosy | No observations |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.4. Antileprosy medicines | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. |
| PAHO Strategic Fund Medicine List | 2.2. Antileprosy med. |
Others observations: Medicines used in the treatment of leprosy should never be used except in combination. |
| Colombia | 01. Leprostatics | No observations |
| Peru | 6.2.3 Anti-Leprosy | No observations |
| Ecuador | Essential Medicines List - Ecuador | No observations |
| Venezuela (incomplete) | List of Generic Medications - Venezuela | No observations |
| Cuba | 6.2.10 Antituberculosos y antileprosos | No observations |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |